Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 14/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 13/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102115 | 0.95 | CHRM2 (0.52) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL1102024 | 0.91 | MEN1 (0.64) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL1102260 | 0.86 | CHRM2 (0.73) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL1102069 | 0.83 | SCN3A (0.55) | MEN1KMT2ARORCSCN9A | |
| SCHEMBL1102070 | 0.81 | CHRM2 (0.65) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL1102131 | 0.80 | MAPT (0.53) | MEN1KMT2AALDH1A1MAPTSCN9A | |
| SCHEMBL1091209 | 0.77 | MEN1 (0.64) | CHRM2CHRM4CHRM1MEN1KMT2A | |
| SCHEMBL1102023 | 0.77 | KMT2A (0.57) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL29930240 | 0.77 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3MEN1 | |
| SCHEMBL28638610 | 0.77 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | CHRM2 1093/4885CHRM4 1075/4885CHRM1 1682/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | CHRM2 1093/4885CHRM4 1075/4885CHRM1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.